Sony, Partners Trial MEA System with 237,000 Electrodes
- Sony Semiconductor Solutions, SCREEN Holdings, and VitroVo jointly announced a trial of a high-density MEA system in Tokyo on June 2, 2025.
- The collaboration, with cooperation from the Tohoku Institute of Technology, developed this system to enable detailed cellular electrical activity observation.
- The CMOS-MEA device uses complementary metal-oxide-semiconductor technology with approximately 237,000 electrodes in a compact design to capture cell firing at high resolution.
- The system allows simultaneous measuring and recording of dense cell activity data, supporting drug discovery, neuronal and cardiac disease research, and serving as an alternative to animal testing.
- Offering the system on a trial basis aims to verify efficacy, promote technical development, accelerate market surveys based on user feedback, and advance commercialization using this MEA innovation.
Insights by Ground AI
Does this summary seem wrong?
58 Articles
58 Articles
All
Left
8
Center
21
Right
5

+56 Reposted by 56 other sources
Sony, SCREEN, and VitroVo to Start Trial Offer of MEA System Capable of Simultaneous Measuring and Recording Data from Approximately 237,000 Electrodes
Contributing to high-definition visualization of cellular activity and supporting research into neuronal and cardiac diseases and drug discovery
Sony, Partners Trial MEA System with 237,000 Electrodes
Cutting-Edge Collaboration: Sony, SCREEN, and VitroVo Unveil Revolutionary Microelectrode Array System In a significant leap forward for medical research and drug development, Japan’s technological titans, Sony Semiconductor Solutions Corporation, SCREEN Holdings Co., Ltd., and VitroVo Inc., have announced the creation of an innovative microelectrode array (MEA) system. This advanced system, featuring a high-density CMOS-MEA equipped […]
Coverage Details
Total News Sources58
Leaning Left8Leaning Right5Center21Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
62% Center
L 24%
C 62%
15%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage